Timeline

Voting rights breakdown

Gemeldete wirtschaftlich Berechtigte · 23

Eine einzelne, gemeinsam eingereichte Meldung: Der Stimmrechtsanteil gilt für die gesamte Gruppe, nicht für jede Person.

• Aravis Venture I LP80.41%
• Astellas Venture Capital, LLC80.41%
• Auriga Ventures III80.41%
• Baltisches Haus Limited80.41%
• BioMedInvest II LP80.41%
• Dansk Innovationsinvestering P/S c/o LD Invest A/S80.41%
• Entrepreneurs Fund General Partners Limited80.41%
• Evolva Holding SA80.41%
• Mona Lisa Capital SA80.41%
• Novartis Bioventures Ltd80.41%
• Renaisance PME fondation suisse d investissement / Mona Lisa80.41%
• Sunstone Life Science Ventures Fund I K/S80.41%
• Symbion Capital I A/S80.41%
• Wellington Partners Ventures III Life Science Fund L.P80.41%
• Wellington Partners Ventures III Life Science Network Fund L80.41%
• Neil Goldsmith80.41%
• Alexandra SantAna Sørensen80.41%
• Pascal Longchamp80.41%
• Jakob Dynnes Hansen80.41%
• Jutta Heim80.41%
• PM Murali80.41%
• Ventureast Trustee Company P Limited80.41%
• APIDC Venture Capital P Limited80.41%

Notice details

Beneficial owner

Aravis Venture I LP

The members of the group (the Lock-up Group) have agreed to partially extend the lock-up undertaking entered into prior to the merger between Arpida Ltd. (now Evolva Holding SA) with Evolva SA with regard to their shares in Evolva Holding SA (the Shares) and conversion rights as follows: - with regard to 45% of their aggregate holdings (i.e., with regard to 51,011,142 Shares and 4,949,046 conversion rights) up to and including May 23, 2011; - with regard to 45% of their aggregate holdings (i.e., with regard to 51,011,141 Shares and 4,949,046 conversion rights) up to and including August 31, 2011 Additional information can be downloaded from the Evolva website (www.evolva.com/ investors/disclosure-shareholdings).